Financials in USD. Standardized financial statements.
A compact view of how NAYA Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $6.53M | $3.02M | $822,196 | $4.16M | $1.04M | $1.48M | $494,375 | $282,145 | $50,901 | $11,689 |
| Revenue Growth? | +116.3% | +267.4% | -80.2% | +301.1% | -29.9% | +199.4% | +75.2% | +454.3% | +335.5% | 0.0% |
| Cost of Revenue? | $3.66M | $1.93M | $850,770 | $145,052 | $88,760 | $139,670 | $90,367 | $51,954 | $15,094 | $7,810 |
| Gross Profit? | $2.87M | $1.09M | -$28,574 | $4.02M | $948,526 | $1.34M | $404,008 | $230,191 | $35,807 | $3,879 |
| Gross Margin? | +44.0% | +36.0% | -3.5% | +96.5% | +91.4% | +90.6% | +81.7% | +81.6% | +70.3% | +33.2% |
| Operating Expenses? | $11.00M | $7.65M | $10.60M | $9.23M | $6.46M | $3.13M | $3.04M | $870,612 | $2.15M | $598,953 |
| Operating Income? | -$8.13M | -$6.77M | -$10.63M | -$5.22M | -$5.51M | -$1.79M | -$2.63M | -$640,421 | -$2.11M | -$595,074 |
| EBITDA? | -$7.14M | -$6.88M | -$10.75M | -$5.22M | -$5.48M | -$1.76M | -$2.63M | -$678,480 | -$2.11M | -$4.92M |
| Income Before Tax | -$9.12M | -$8.01M | -$10.89M | -$6.65M | -$8.35M | -$2.17M | -$3.08M | -$702,163 | -$2.12M | -$4.96M |
| Income Tax Expense | -$22,913 | $27,786 | $2,872 | $4,764 | $36 | $433 | $0 | $0 | $0 | $0 |
| Net Income? | -$9.10M | -$8.03M | -$10.89M | -$6.65M | -$8.35M | -$2.17M | -$3.08M | -$702,163 | -$2.12M | -$4.96M |
| EPS? | $-30.19 | $-5.13 | $-8.99 | $-6.26 | $-15.21 | $-4.46 | $-6.68 | $-1.59 | $-6.40 | $-12.80 |
| Diluted EPS? | $-30.19 | $-5.13 | $-8.99 | $-6.26 | $-15.21 | $-4.46 | $-6.68 | $-1.59 | $-6.40 | $-12.80 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality